418 related articles for article (PubMed ID: 12412156)
1. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and cisplatin in patients with non-small cell lung cancer: results of a phase II trial.
von Pawel J; Wagner H; Niederle N; Heider A; Koschel G; Gromotka E; Hanske M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):7-9. PubMed ID: 8941403
[TBL] [Abstract][Full Text] [Related]
7. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
[TBL] [Abstract][Full Text] [Related]
9. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
[TBL] [Abstract][Full Text] [Related]
10. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.
Hanauske AR; Schilling T; Heinrich B; Kau R; Herzog M; Quasthoff S; Bochtler H; Diergarten K; Rastetter J
Semin Oncol; 1995 Dec; 22(6 Suppl 14):35-9. PubMed ID: 8553082
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
Panagos GE
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S17-21. PubMed ID: 9071335
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion.
Tester WJ; Jin PY; Reardon DH; Cohn JB; Cohen MH
Cancer; 1997 Feb; 79(4):724-9. PubMed ID: 9024710
[TBL] [Abstract][Full Text] [Related]
13. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
14. Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors.
Brun B; Benchalal M; Lebas C; Piedbois P; Lin M; Lebourgeois JP
Cancer; 1997 Jun; 79(11):2137-46. PubMed ID: 9179060
[TBL] [Abstract][Full Text] [Related]
15. [Experience in treatment of patients with locally advanced or recurrent breast cancer: intraarterial infusion chemotherapy combined with radiotherapy].
Murakami M; Yoden E; Kono K; Okamoto Y; Maetani Y; Sai H; Kobayashi K; Sasaki R; Kazawa N; Sano A; Kuroda Y
Nihon Igaku Hoshasen Gakkai Zasshi; 1997 Mar; 57(4):189-94. PubMed ID: 9125875
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
Goldberg JM; Piver MS; Hempling RE; Recio FO
Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
[TBL] [Abstract][Full Text] [Related]
18. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.
Lippman ME; Sorace RA; Bagley CS; Danforth DW; Lichter A; Wesley MN
NCI Monogr; 1986; (1):153-9. PubMed ID: 3022156
[TBL] [Abstract][Full Text] [Related]
19. A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma.
Pisansky TM; Loprinzi CL; Cha SS; Fitzgibbons RJ; Grant CS; Hass AC; Reuter NF; Wold LE; Ingle JN; Kardinal CG
Cancer; 1996 Jun; 77(12):2520-8. PubMed ID: 8640701
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
Johnson DH; Paul D; Hande KR
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S22-5. PubMed ID: 9071336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]